LIBTAYO: the first and only FDA-approved therapy for patients with advanced cutaneous squamous cell carcinoma (CSCC)1

LIBTAYO® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Review clinical study design Explore clinical study efficacy data Explore clinical study safety data

Effective April 1, 2019

LIBTAYO C-code available


LIBTAYO (cemiplimab-rwlc) packaging
  1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC.